RESEARCH ARTICLE | DOI: https://doi.org/PP-CCRCP-RA-0001
1.Department of Cardiology, Meridian University Medical Center, New York, USA
2.Department of Internal Medicine, University Hospital of Central Texas, Austin, USA
3.Department of Epidemiology and Public Health, Instituto Nacional de Salud, Mexico City, Mexico
4.Department of Pharmacology, Eastbridge College of Pharmacy, Toronto, Canada
*Corresponding Author: John M. Patterson, Department of Cardiology, Meridian University Medical Center, New York, USA
Citation: John M. Patterson, Aisha Rahman, Carlos Rivera, Emily Zhang (2025) Heart Failure: Clinical Insights into Diagnosis, Management, and Outcomes, J. Clinical Case Reports and Clinical Practice 1(1): dx.doi.org/CCRCP/PP.0001
Copyright 
:
© John M. Patterson.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 10 June 2025 | Accepted: 15 June 2025 | Published: 24 June 2025
Keywords: heart failure, left ventricular dysfunction, ejection fraction, diuretics, beta-blockers, cardiomyopathy, clinical outcomes, chronic heart disease
Heart failure (HF) is a complex clinical syndrome resulting from structural or functional cardiac disorders that impair the heart's ability to pump blood efficiently. Despite advances in diagnosis and treatment, heart failure remains a leading cause of morbidity and mortality worldwide. This study explores the clinical characteristics, diagnostic strategies, treatment modalities, and patient outcomes associated with heart failure. A retrospective observational study was conducted on 250 patients diagnosed with heart failure between January 2021 and December 2023. Data analysis focused on clinical presentation, comorbidities, echocardiographic findings, pharmacological interventions, and 12-month outcomes. The findings highlight the importance of early diagnosis, individualized management, and patient education in improving quality of life and reducing hospital readmissions. Further research is needed to optimize therapeutic strategies and integrate emerging treatments
Heart failure (HF) is a global health challenge affecting more than 64 million people worldwide. It is characterized by the heart's inability to pump sufficient blood to meet the body's metabolic needs. HF can be classified as heart failure with reduced ejection fraction (HFrEF), preserved ejection fraction (HFpEF), or mildly reduced ejection fraction (HFmrEF), based on echocardiographic measurements. Contributing factors include ischemic heart disease, hypertension, diabetes mellitus, valvular heart disease, and cardiomyopathies. Patients typically present with symptoms such as dyspnea, fatigue, and fluid retention. Despite therapeutic advances, heart failure is associated with high rates of hospitalizations and mortality. Early diagnosis and evidence-based management strategies are essential for improving prognosis. This study aims to evaluate the clinical profile, management practices, and outcomes of heart failure patients in a tertiary care setting, contributing to the growing body of knowledge needed to enhance patient care.
Study Design and Setting
This retrospective observational study was conducted at the Meridian University Medical Center between January 2021 and December 2023.
Study Population
A total of 250 patients aged 18 years and older, diagnosed with heart failure (both new-onset and chronic), were included. Diagnosis was based on Framingham criteria and echocardiographic confirmation of ventricular dysfunction.
Data Collection
Patient data were extracted from hospital electronic medical records, including:
Ethical Considerations
The study protocol was approved by the institutional ethics committee. Patient confidentiality was maintained throughout the data collection and analysis process.
Statistical Analysis
Descriptive statistics were used for demographic and clinical variables. Chi-square and t-tests were applied for categorical and continuous variables respectively. A p-value < 0>
The study included 250 patients (62% male, 38
The findings of this study underscore the multifactorial nature of heart failure and the critical need for comprehensive, individualized treatment approaches. The predominance of HFrEF aligns with global epidemiological patterns, with ischemic heart disease and hypertension as leading contributors. Our data highlight the high utilization of evidence-based pharmacologic therapies, particularly beta-blockers and ACE inhibitors. The gradual adoption of newer agents like ARNIs reflects growing adherence to updated HF guidelines, although access and cost remain limiting factors in some settings. The relatively low 12-month mortality (8.4%) compared to prior studies may reflect improvements in care coordination and patient follow-up. However, rehospitalization rates remain a concern, emphasizing the importance of outpatient monitoring and patient education. Our study supports the ongoing emphasis on early diagnosis, aggressive risk factor management, and patient-centered care in HF management. Future research should focus on integrating biomarkers, digital health tools, and tailored interventions to further improve outcomes.
Heart failure remains a complex and prevalent condition with significant clinical implications. This study reinforces the importance of structured diagnostic assessment, optimized pharmacologic therapy, and close follow-up to improve patient outcomes. As the field evolves, incorporating novel therapies and technologies into routine care may further enhance quality of life and survival among patients with heart failure.
